



PRESS RELEASE

Samumed Announces 52-week Phase 2 Osteoarthritis Data Supporting the Potential of SM04690 as a Disease Modifying Drug

- SM04690 exhibited clinically meaningful and significant improvements in pain, function, and joint space width in unilateral symptomatic osteoarthritis patients -
- Samumed will be presenting data in three presentations at the 2017 ACR/ARHP Annual Meeting -

SAN DIEGO – Oct. 24, 2017 – Samumed, LLC, today announces highlights from its 52-week Phase 2 proof-of-concept study of SM04690 in osteoarthritis (OA) of the knee, lending support to SM04690’s potential as a disease modifying osteoarthritis drug (DMOAD). In unilateral symptomatic knee OA patients, one of the three doses (0.07mg) of a single intra-articular injection of SM04690 showed clinically meaningful and significant improvements compared to placebo in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function scores. In the same prespecified patient population, SM04690 potentially maintained or increased medial joint space width (mJSW) compared to placebo, where changes in mJSW were predictive of WOMAC pain and function improvement.

Similar trends were observed in the intent to treat (ITT) group, as well as in the other two doses studied. Detailed results from the 52-week study will be presented at the 2017 ACR/ARHP Annual Meeting being held on Nov. 3-8 in San Diego:

Oral presentation

Presentation Title: [Results from a 52 Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor \(SM04690\) for the Treatment of Knee Osteoarthritis](#)

Presenter: Yusuf Yazici, M.D.

Session Title: Osteoarthritis – Clinical Aspects I: Structural Progression & Incidence

Date/Time: Sunday, Nov. 5, at 5:30 p.m. PST

Abstract Number: 935

Poster presentations

Presentation Title: [Reducing Heterogeneity in OA Clinical Trials: Data from a Phase 2 Study of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor in Knee Osteoarthritis](#)

Session Title: Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions

Date/Time: Monday, Nov. 6, from 9-11 a.m. PST



Abstract Number: 1201

Presentation Title: [Radiographic Outcomes Were Associated with Pain and Function Responses: Post-Hoc Analysis of Results from a Phase 2 Study of a Small Molecule Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment](#)

Session Title: Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions

Date/Time: Monday, Nov. 6, from 9-11 a.m. PST

Abstract Number: 1204

About SM04690

SM04690 is a small molecule inhibitor of the Wnt pathway administered as an intra-articular injection, and is being developed as a potential disease modifying drug for osteoarthritis (DMOAD). Preclinical data suggest SM04690 has a dual mechanism of action with three specific effects on joint health – generating new articular cartilage, slowing down cartilage degradation, and reducing inflammation in the joint. Additional information on Samumed’s SM04690

Osteoarthritis program can be found here:

<https://www.samumed.com/pipeline/detail.aspx?id=20>

About Samumed

Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Samumed’s clinical pipeline can be found here: <https://www.samumed.com/pipeline/default.aspx>

Corporate Contact:

Erich Horsley
Samumed, LLC
erich@samumed.com
858-365-0200

Investor Contact:

Ashley Robinson
LifeSci Advisors
arr@lifesciadvisors.com
617-535-7742

Media Contact:

Matt Middleman, M.D.
LifeSci Public Relations
matt@lifescipublicrelations.com
646-627-8384